Do Hedge Funds Love Tokai Pharmaceuticals Inc (TKAI)?

Page 1 of 2

It was a rough third quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 7% during the quarter. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by about 14 percentage points between June 25 and October 30, as investors fled less-known quantities for safe havens. This was the case with hedge funds, who we heard were pulling money from the market amid the volatility, which included money from small-cap stocks, which they invest in at a higher rate than other investors. This action contributed to the greater decline in these stocks during the tumultuous period. We will study how this market volatility affected their sentiment towards Tokai Pharmaceuticals Inc (NASDAQ:TKAI) during the quarter below.

Tokai Pharmaceuticals Inc (NASDAQ:TKAI) shares haven’t seen a lot of action during the third quarter. Overall, hedge fund sentiment was unchanged. The stock was in 7 hedge funds’ portfolios at the end of the third quarter of 2015. At the end of this article, we will also compare Tokai Pharmaceuticals Inc (NASDAQ:TKAI) to other stocks, including MCBC Holdings Inc (NASDAQ:MCFT), Mazor Robotics Ltd – ADR (NASDAQ:MZOR), and Fluidigm Corporation (NASDAQ:FLDM) to get a better sense of its popularity.

Follow Eledon Pharmaceuticals Inc. (NASDAQ:ELDN)

In the 21st century investor’s toolkit, there are many methods shareholders can use to assess publicly traded companies. A duo of the most under-the-radar methods are hedge fund and insider trading moves. Our experts have shown that, historically, those who follow the best picks of the elite hedge fund managers can outclass the broader indices by a significant margin (see the details here).

Now, let’s take a look at the latest action encompassing Tokai Pharmaceuticals Inc (NASDAQ:TKAI).

How have hedgies been trading Tokai Pharmaceuticals Inc (NASDAQ:TKAI)?

At the end of the third quarter, a total of 7 of the hedge funds tracked by Insider Monkey held long positions in this stock, unchanged from the second quarter. With hedgies’ capital changing hands, there exists a few notable hedge fund managers who were upping their stakes meaningfully (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Mark Kingdon’s Kingdon Capital has the number one position in Tokai Pharmaceuticals Inc (NASDAQ:TKAI), worth close to $6.8 million, accounting for 0.3% of its total 13F portfolio. Coming in second is Sabby Capital, managed by Hal Mintz, which holds a $6.8 million position; 0.3% of its 13F portfolio is allocated to the stock. Remaining hedge funds and institutional investors that hold long positions encompass Joseph Edelman’s Perceptive Advisors, Anand Parekh’s Alyeska Investment Group, and Ross Berman’s Green Owl Capital Management.

Page 1 of 2